UNSPSC 51122600: Combination antilipemic agents

This classification denotes combination drugs that lower the levels of certain lipids (or alcohol-ether-soluble constituents of protoplasm) in the blood, such as fats, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids, and which therefore treat hyperlipidemia, hence the term ANTILIPEMIC AGENTS. Typical combination antilipemic agent constituents are aspirin, cholestyramine, ezetimibe, lovastatin, and niacin.

UNSPSC 51122600 Combination antilipemic agents is a Class code that does not reflect the actual procurement activity tagged under it in recent state and local solicitations. The City of Tampa's April 2026 IFB for Advanced Life Support Medications (Bid No. 26-P-00188) requesting Labetalol, Epinephrine, Adenosine, and Diltiazem represents emergency medical supplies for fire rescue operations, not antilipemic agents used to treat high cholesterol and lipid disorders. The scope mismatch suggests either a data-entry error in the tagging or a categorical misalignment between the code definition and current procurement practice. The Tampa opportunity itself is a straightforward goods procurement with firm pricing, nine-month minimum shelf life, ten-day delivery, and a one-year initial term with two optional one-year renewals and up to three 30-day extensions; the City applied a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation not to exceed $10,000.

The single recent opportunity in the source reflects activity in Florida, with an estimated contract value of $40,000. Because the medication line items (vasopressor and antiarrhythmic agents) fall outside the code's stated focus on antilipemic compounds, this code shows little relevant recent activity for business development purposes under its nominal scope. Vendors pursuing emergency medical supply contracts with fire departments and EMS agencies should monitor state and local procurement channels directly rather than rely on this code classification.